PPAR2 Regulates a Molecular Signature of Marrow Mesenchymal Stem Cells
Open Access
- 23 August 2007
- journal article
- research article
- Published by Hindawi Limited in PPAR Research
- Vol. 2007, 1-13
- https://doi.org/10.1155/2007/81219
Abstract
Bone formation and hematopoiesis are anatomically juxtaposed and share common regulatory mechanisms. Bone marrow mesenchymal stromal/stem cells (MSC) contain a compartment that provides progeny with bone forming osteoblasts and fat laden adipocytes as well as fibroblasts, chondrocytes, and muscle cells. In addition, marrow MSC provide an environment for support of hematopoiesis, including the development of bone resorbing osteoclasts. The PPAR2 nuclear receptor is an adipocyte-specific transcription factor that controls marrow MSC lineage allocation toward adipocytes and osteoblasts. Increased expression of PPAR2 with aging correlates with changes in the MSC status in respect to both their intrinsic differentiation potential and production of signaling molecules that contribute to the formation of a specific marrow microenvironment. Here, we investigated the effect of PPAR2 on MSC molecular signature in respect to the expression of gene markers associated exclusively with stem cell phenotype, as well as genes involved in the formation of a stem cell supporting marrow environment. We found that PPAR2 is a powerful modulator of stem cell-related gene expression. In general, PPAR2 affects the expression of genes specific for the maintenance of stem cell phenotype, including LIF, LIF receptor, Kit ligand, SDF-1, Rex-1/Zfp42, and Oct-4. Moreover, the antidiabetic PPARagonist TZD rosiglitazone specifically affects the expression of “stemness” genes, including ABCG2, Egfr, and CD44. Our data indicate that aging and antidiabetic TZD therapy may affect mesenchymal stem cell phenotype through modulation of PPAR2 activity. These observations may have important therapeutic consequences and indicate a need for more detailed studies of PPAR2 role in stem cell biology.
Keywords
Funding Information
- National Institute on Aging (R01AG17482, R01 AG028935, 1-03-RA-46, HG003968)
This publication has 51 references indexed in Scilit:
- Rosiglitazone Induces Decreases in Bone Mass and Strength that Are Reminiscent of Aged BoneEndocrinology, 2007
- Activation of Peroxisome Proliferator-Activated Receptor γ (PPARγ) by Rosiglitazone Suppresses Components of the Insulin-Like Growth Factor Regulatory System in Vitro and in VivoEndocrinology, 2007
- Thiazolidinedione Use and Bone Loss in Older Diabetic AdultsJournal of Clinical Endocrinology & Metabolism, 2006
- Cell Surface and Transcriptional Characterization of Human Adipose‐Derived Adherent Stromal (hADAS) CellsThe International Journal of Cell Cloning, 2005
- The transactivating function of peroxisome proliferator‐activated receptor γ is negatively regulated by SUMO conjugation in the amino‐terminal domainGenes to Cells, 2004
- A Stem Cell Molecular SignatureScience, 2002
- "Stemness": Transcriptional Profiling of Embryonic and Adult Stem CellsScience, 2002
- Pluripotency of mesenchymal stem cells derived from adult marrowNature, 2002
- Differential Gene Regulation by PPAR Agonist and Constitutively Active PPAR 2Molecular Endocrinology, 2002
- PPARγ3 mRNA: a distinct PPARγ mRNA subtype transcribed from an independent promoterFEBS Letters, 1998